Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Norfenefrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.61 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.58 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.58 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.58 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.58 |
| ▸ | ADRB3 known ✓ | P13945 | 2/20 | 0.58 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.58 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.58 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.58 |
| ▸ | ADRA1B known ✓ | P35368 | 2/20 | 0.58 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.58 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.58 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.58 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.55 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.55 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.55 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.55 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.52 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Norfenefrine SCHEMBL1650723 | 1.00 | HIF1A (0.61) | HIF1ABLMLMNAKDM4EGAA | |
| Norfenefrine SCHEMBL1797532 | 0.98 | HIF1A (0.59) | HIF1ABLMLMNAKDM4EGAA | |
| Norfenefrine SCHEMBL29394995 | 0.98 | HIF1A (0.59) | HIF1ABLMLMNAKDM4EGAA | |
| Norfenefrine SCHEMBL153494 | 0.98 | HIF1A (0.59) | HIF1ABLMLMNAKDM4EGAA | |
| Norfenefrine SCHEMBL15485360 | 0.98 | HIF1A (0.59) | HIF1ABLMLMNAKDM4EGAA | |
| Norfenefrine SCHEMBL9639702 | 0.98 | HIF1A (0.59) | HIF1ABLMLMNAKDM4EGAA | |
| Norfenefrine SCHEMBL30389272 | 0.98 | HIF1A (0.59) | HIF1ABLMLMNAKDM4EGAA | |
| Norepinephrine SCHEMBL2838434 | 0.88 | BLM (0.77) | HIF1ABLMLMNAKDM4EGAA | |
| SCHEMBL2150842 | 0.82 | HIF1A (0.56) | HIF1ABLMLMNAKDM4EGAA | |
| SCHEMBL17735450 | 0.82 | HIF1A (0.56) | HIF1ABLMLMNAKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100361962-C | Preparation method of demebeverine hydrochloride | XINJIANG INST OF PHYSICAL AND (CN) | 2008-01-16 | — | — | CN | claimed |
| CN-1824645-A | Preparation method of demebeverine hydrochloride | XINJIANG INST OF PHYSICAL AND (CN) | 2006-08-30 | — | — | CN | claimed |
| EP-1267828-B1 | PHARMACEUTICAL PREPARATIONS CONTAINING SACCHAROSE FATTY ACID ESTERS FOR CONTROLLING THE RELEASE OF ACTIVE INGREDIENTS | AWD PHARMA GMBH & CO KG (DE) | 2006-08-02 | — | — | EP | claimed |
| EP-1420021-A1 | DNA Methyltransferase inhibitors | The Penn State Research Foundation (US) | 2004-05-19 | — | — | EP | claimed |
| CN-1370170-A | DNA methyltransferase inhibitors | PENN STATE RES FOUND (US) | 2002-09-18 | — | — | CN | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0189861-A2 | Percutaneous absorption accelerator for ionic water-soluble medicine | SHOWA DENKO KABUSHIKI KAISHA (JP) | 1986-08-06 | — | — | EP | claimed |
| JP-6336429-A | — | — | None | — | — | JP | disclosed |
| US-20220081737-A1 | POND REACTOR FOR RECOVERY OF METALS | CYCAD GROUP, LLC | 2022-03-17 | — | — | US | disclosed |
| CN-111606815-B | Preparation method of phenylephrine hydrochloride impurity standard | 珠海安哲生物科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210340025-A1 | Compositions and Methods for Purification of Metals from Steel Making Waste Streams | CYCAD GROUP, LLC | 2021-11-04 | — | — | US | disclosed |
| EP-3853177-A1 | COMPOSITIONS AND METHODS FOR PURIFICATION OF METALS FROM STEEL MAKING WASTE STREAMS | Lixivia, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-111606815-A | Preparation method of phenylephrine hydrochloride impurity standard | 珠海安哲生物科技有限公司 | 2020-09-01 | — | — | CN | disclosed |
| EP-0043254-B1 | RETARDED RELEASE PHARMACEUTICAL COMPOSITION AND PROCESS FOR PRODUCING THE SAME | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1984-05-30 | — | — | EP | disclosed |
| EP-0103830-A2 | Phenylethylemine derivatires as growth stimulators | BAYER AG (DE) | 1984-03-28 | — | — | EP | disclosed |
| US-4322423-A | 4-Phenyl-4,5,6,7-tetrahydro-thieno(2,3-C)pyridines and salts thereof | BOEHRINGER INGELHEIM GMBH (DE) | 1982-03-30 | — | — | US | disclosed |
| EP-0043254-A1 | Retarded release pharmaceutical composition and process for producing the same | GÖDECKE AKTIENGESELLSCHAFT (DE) | 1982-01-06 | — | — | EP | disclosed |
| US-3989836-A | HYPERTENSIVE AGENTS | WARNER-LAMBERT COMPANY (US) | 1976-11-02 | — | — | US | disclosed |
| US-3966813-A | Process for the preparation of 1-(m- and p-hydroxyphenyl)-2-aminoethanol | WARNER-LAMBERT COMPANY (US) | 1976-06-29 | — | — | US | disclosed |
| US-3931212-A | Method for treating cardiovascular circulatory insufficiencies and hypotonia with 2-hydroxy-phenyl-1-oxa-4-azaspiroalkane derivatives | WARNER-LAMBERT COMPANY (US) | 1976-01-06 | — | — | US | disclosed |